Medi-tate wins EU CE Mark for prostrate device

The company's mechanical Benign Prostate Hyperplasia device is for a minimally invasive procedure to reshape the urethra.

Medi-tate Ltd. has obtained EU CE Mark certification for its mechanical Benign Prostate Hyperplasia (BPH) device for a minimally invasive procedure to reshape the urethra. Medi-tate offers a unique solution to patients and urologists, achieving surgery-like results using a minimally invasive office procedure and avoiding traumatic tissue cutting, heavy sedation and hospitalization. Patients enjoy immediate return to normal activities and reduced side effects.

Medi-tate CTO Ido Kilemnik and VP regulatory affairs Dr. Rami Biran founded the company at the Xenia Venture Capital Ltd. (TASE:XENA) incubator in 2007. Medi-tate says that 15 million American men have BPH symptom, only one fifth of whom are treated, and one tenth of them by surgery. The US BPH market totals more than $3 billion a year, including $1 billion for surgical procedures.

Medi-tate is the latest Xenia portfolio company to obtain CE Mark certification. It follows Xenolith Medical Ltd. for its filters against kidney stones during ureteroscopic kidney and bladder procedures, Ortho-Space Ltd. for its SpaceGuard Balloon biodegradable implants to protect tissue during radiotherapy, and Neatstitch Ltd. for its Neatclose automatic suturing product for laparoscopic procedures.

Published by Globes [online], Israel business news - - on February 5, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018